Clinical trials: sponsored by Centre for Addiction and Mental Health
Treatment Resistant Schizophrenia, Schizophrenia
Magnetic Seizure Therapy for Schizophrenia - Trial
This trial aims to assess the clinical effects and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for Treatment Resistant Schizophrenia (RS).
- Conditions
- Treatment Resistant Schizophrenia, Schizophrenia, Schizoaffective Disorder
- Trial name
- MAST (NCT06672588)
- Testing
- Magnetic Seizure Therapy (MST), Electroconvulsive Therapy (ECT)
- Where
- 2 sites in Canada
- Volunteers
- 80 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD)
Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder
The goal of this clinical trial is to determine the safety and efficacy of psilocybin assisted Therapy (PAT) in individuals with comorbid Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD).
- Trial name
- NCT07405606
- Testing
- Psilocybin 25 mg
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre for Addiction and Mental Health
Treatment Resistant Depression, Autism Spectrum Disorder
Psilocybin for Treatment-Resistant Depression in Autism
We propose a first-of-its-kind open-label clinical trial to investigate the feasibility, tolerability, and safety of administering psilocybin in autistic adults with treatment-resistant depression (TRD).
- Trial name
- PAT-DA (NCT06731621)
- Testing
- Psilocybin
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- Centre for Addiction and Mental Health
PTSD, Cannabis Use
Effect of Extended Cannabis Abstinence on PTSD Symptoms
This will be a 12-week randomized trial. Outpatients and patients from the Mood and Anxiety program at the Centre for Addiction and Mental Health (CAMH) with a current diagnosis of post-traumatic stressed disorder (PTSD) and…
- Conditions
- PTSD, Cannabis Use, Cognitive Symptom, Comorbidities and Coexisting Conditions
- Trial name
- CANPOST (NCT05162651)
- Testing
- Contingency-management, Enhanced usual care
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Centre for Addiction and Mental Health
Mental Disorders, Addiction
Integrated Collaborative Care Teams for Youth With Mental Health and/or Addiction Challenges (YouthCan IMPACT)
Among youth, the prevalence of mental health and addiction (MHA) disorders is roughly 20%, yet youth are challenged to access services in a timely fashion.
- Trial name
- NCT02836080
- Testing
- Integrated Collaborative Care Team (ICCT), Treatment as Usual (TAU)
- Where
- 5 sites in Canada
- Volunteers
- 247 people
- Sponsor
- Centre for Addiction and Mental Health
Bipolar Disorder, Multiple Mental Health Conditions
Narrative Enhancement and Cognitive Therapy for Self-Stigma in Youth
The goal of this pilot clinical trial is to assess the feasibility of conducting a full-scale study to learn if a new youth-adapted Narrative Enhancement and Cognitive Therapy (NECT-Y) reduces self-stigma in youth living with…
- Trial name
- NCT06672562
- Testing
- Narrative Enhancement and Cognitive Therapy, Usual care
- Where
- Canada
- Volunteers
- 97 people
- Sponsor
- Centre for Addiction and Mental Health
Late Life Depression (LLD), Depression - Major Depressive Disorder
Accelerated vs. Conventional Theta Burst Stimulation for Late-life Depression
The purpose of this trial is to compare the treatment efficacy (improvement in depressive symptoms) of accelerated TBS protocol (where participants receive multiple TBS treatments daily) to conventional TBS protocol (where…
- Conditions
- Late Life Depression (LLD), Depression - Major Depressive Disorder, Depressive Disorder, Treatment-Resistant, Mood Disorders
- Trial name
- ACT-LLD (NCT06854367)
- Testing
- TBS
- Where
- 2 sites in Canada
- Volunteers
- 280 people
- Sponsor
- Centre for Addiction and Mental Health
Treatment Resistant Depression, Chronic Pain
Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects.
- Trial name
- TRANSCEND (NCT06518720)
- Testing
- Psilocybin 25 mg
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Centre for Addiction and Mental Health
Mild Cognitive Impairment (MCI), Alzheimer Disease (AD)
Remote Digital Assessments for Cognitive Disorders
Memory and thinking problems in older adults, including mild cognitive impairment (MCI) and Alzheimer's disease (AD), can be difficult to assess promptly because evaluation often depends on in-person specialist visits.
- Trial name
- MonitorCog-AI (NCT07883746)
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Healthy Controls
Intranasal Insulin and Olanzapine Study in Healthy Volunteers
Antipsychotic (AP) medications are considered to be the gold standard treatment for psychotic disorders including schizophrenia.
- Trial name
- INI/OLA (NCT03741478)
- Testing
- OLANZapine 2.5 MG, Insulin Lispro 100 UNT/ML, Saline
- Where
- 2 sites in Canada
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Treatment Resistant Depression
Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects.
- Trial name
- SYNVEST (NCT06512220)
- Testing
- Psilocybin 25 mg, Risperidone 1 MG
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Centre for Addiction and Mental Health
Knowledge Gaps, Attitudes
Addiction Psychoeducation for Canadian Muslims
The Canadian Muslim Addiction Program (C-MAP) was designed as a pilot randomized controlled study using quantitative and qualitative methods to evaluate culturally and spiritually adapted addiction psychoeducation.
- Conditions
- Knowledge Gaps, Attitudes, Stigma of Mental Illness, Help-seeking Intention
- Trial name
- NCT07865104
- Testing
- Culturally sensitive addiction psychoeducation program, Secular
- Where
- Canada
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Bipolar Depression, Bipolar Disorder
Theta-Burst Stimulation for Bipolar Depression
The purpose of this trial is to determine if intermittent theta-burst stimulation (iTBS) can reduce the symptoms of depression in treatment-resistant bipolar disorder.
- Conditions
- Bipolar Depression, Bipolar Disorder, Treatment- Resistant Bipolar Disorder, Type 2 Bipolar Disorder
- Trial name
- TRIBE (NCT06370988)
- Testing
- iTBS Stimulation
- Where
- 2 sites in Canada
- Volunteers
- 124 people
- Sponsor
- Centre for Addiction and Mental Health
Amnestic Mild Cognitive Impairment
Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment
The goal of this pilot, exploratory, clinical trial is to investigate the effects of psilocybin on synaptic vesicular density (SVD) as measured by the positron emission tomography (PET) radiotracer, 18F-SynVesT-1, in participants…
- Trial name
- NCT06041152
- Testing
- Psilocybin
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Bipolar Disorder
Dialectical Behavior Therapy for Youth With and/or at Familial Risk for Bipolar Disorder
Dialectical behavior therapy (DBT) will be conducted over 1 year in youth with and/or at familial risk for bipolar disorder (BD).
- Trial name
- DB1 (NCT05153382)
- Testing
- Dialectical behavioral therapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Centre for Addiction and Mental Health
Bipolar Disorder
Pragmatic Patient-oriented Extension Study of Dialectical Behavior Therapy Booster Sessions for Youth With and/or at Familial Risk for Bipolar Disorder
The study intervention is DBT adapted for youth with and/or at familial risk for bipolar disorder. Participants will have completed one full year of DBT in a previous study. This study is examining use of booster sessions.
- Trial name
- DB2 (NCT05627492)
- Testing
- Dialectical behavioral therapy
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Centre for Addiction and Mental Health
Bipolar Disorder
Three-level Model of DBT-informed Care for Youth With and/or at Familial Risk for Bipolar Disorder (DB3)
This study seeks to bridge the knowledge-to-action gap regarding psychosocial treatment "dosing" for youth with and/or at familial risk for bipolar disorder (BD).
- Trial name
- DB3 (NCT05153369)
- Testing
- Enhanced Care, DBT Skills Training, Dialectical Behavior Therapy Full Intervention
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Centre for Addiction and Mental Health
Insulin Resistance, Menstrual Cycle
Effects of Antipsychotics on Brain Insulin Action in Females
Females treated with antipsychotics have higher rates of comorbid metabolic syndrome than males. Despite this, females have historically been excluded from many mechanistic studies due to confounding effects of menstrual cycles.
- Conditions
- Insulin Resistance, Menstrual Cycle, Type 2 Diabetes, Antipsychotics
- Trial name
- NCT06251635
- Testing
- Olanzapine 2.5Mg Oral Tablet, Insulin Lispro 100 UNT/ML, Saline
- Where
- Canada
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Healthy
Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia
Cognitive impairment (such as challenges in thinking and memory) is a core aspect of schizophrenia (SCZ), contributing to disability and poor functional outcomes.
- Trial name
- NCT05748990
- Testing
- Intranasal insulin
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Obsessive-Compulsive Disorder
Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects.
- Trial name
- PAP-OCD (NCT06299319)
- Testing
- Psilocybin
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Centre for Addiction and Mental Health